All In Biotech

Drug Trial Radar · NCT03441581

Eluxadoline Bile Acid Malabsorption (BAM) Study

3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM)

Last checked: Nov 20, 2026Latest source record: May 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Feb 23, 2018

Primary completion

Apr 28, 2020

Study completion Apr 28, 2020

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the possibility of a differential effect of eluxadoline on altered bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) participants with and without evidence of Bile Acid Malabsorption (BAM).

Conditions

  • Irritable Bowel Syndrome With Diarrhea

Interventions

  • EluxadolineDrug

    Eluxadoline 100 mg oral tablets BID with food.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score Over 4 Weeks of Treatment PeriodTime frame: Baseline (Day 1) to Week 4
  2. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline (Day 1) to Week 4
  3. Number of Participants Who Experienced Potentially Clinically Significant Change in Laboratory TestsTime frame: Baseline (Day 1) to Week 4
  4. Number of Participants Who Experienced Potentially Clinically Significant Change in Vital SignsTime frame: Baseline (Day 1) to Week 4
  5. Number of Participants Who Experienced Clinically Significant Change From Baseline in General Physical Condition as Measured Through General Physical ExamTime frame: Baseline (Day 1) to Week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.